葛兰素史克Glaxosmithkline（GSK）2025年第一季度财报「LSE」（英文版）（50页）.pdf

1、GSK makes strong start to 2025 with growth in sales,profits and earningsSpecialty Medicines growth drives Q1 performanceTotal Q1 sales 7.5 billion+2%AER;+4%CERSpecialty Medicines sales 2.9 billion(+17%);Respiratory,Immunology and Inflammation 0.8 billion(+28%);Oncology 0.4 billion(+53%);HIV sales 1.

2、7 billion(+7%)Vaccines sales 2.1 billion(-6%);Shingrix 0.9 billion(-7%);Meningitis vaccines 0.4 billion(+20%);and Arexvy 0.1 billion(-57%)General Medicines sales 2.5 billion(stable);Trelegy 0.7 billion(+15%)Total operating profit+50%and Total EPS+56%driven by lower CCL chargesCore operating profit+5

3、%and Core EPS+5%reflecting strong Specialty Medicines performance and disciplined increased investment in R&D portfolio progression,new asset launches and growth assets Cash generated from operations exceeded 1 billion with free cash flow of 0.7 billion(Financial Performance Q1 2025 results unless o

4、therwise stated,growth%and commentary at CER as defined on page 44).Q1 2025m%AER%CERTurnover 7,516 2 4 Total operating profit 2,216 49 50 Total operating margin%29.5%9.2ppts 9.0ppts Total EPS 39.7p 55 56 Core operating profit 2,533 4 5 Core operating margin%33.7%0.5ppts 0.3ppts Core EPS 44.9p 4 5 Ca

5、sh generated from operations 1,301 16 Pipeline progress and investment delivering future growth opportunities:5 major new FDA product approvals expected in 2025:Q1 2025 approvals:Penmenvy,meningitis vaccine;Blujepa,first-in-class antibiotic treatment for uUTIsPositive ACIP recommendations for Penmen

6、vy(and Arexvy(adults 50-59)Further approvals expected for:Nucala(COPD);Blenrep(multiple myeloma);and depemokimab(severe asthma and nasal polyps)14 key opportunities expected to launch 2025-2031 each with PYS potential above 2 billionData presented at CROI for VH184,VH499 and N6LS support development